文献速递前列腺癌

先进分子影像检测与传统影像检测的异时性寡转移性去势敏感性前列腺癌的临床与基因组差异

Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
PubMed 文献 · Eur Urol · 2023-05-10

本研究为国际多机构回顾性分析,纳入295例异时性寡转移性去势敏感性前列腺癌(omCSPC)患者,比较先进分子影像(AMIM)单独检出与传统影像(CIM)检出者的临床与基因组特征。CIM检出者Gleason分级分组更高(p=0.032)、确诊时前列腺特异性抗原更高(8.0 vs 1.7 ng/ml;p<0.001)、致病性TP53突变更常见(28% vs 17%;p=0.030)、10年总生存更差(85% vs 100%;p<0.001)。

要点

  • CIM检出omCSPC者确诊时PSA为8.0 ng/ml,AMIM检出者为1.7 ng/ml(p<0.001)。
  • CIM检出者致病性TP53突变占28%,AMIM检出者占17%(p=0.030)。
  • CIM检出者10年总生存为85%,AMIM检出者为100%(p<0.001)。

核心结论

  • AMIM检测与CIM检测的omCSPC存在临床和生物学差异,AMIM检出者高危DNA突变较少且生存更好。
  • 这是首次报告AMIM检出与CIM检出omCSPC之间临床和生物学差异的研究。
  • 作者认为该发现对正在开展和计划中的omCSPC临床试验尤为重要。

研究设计与样本

  • 国际多机构回顾性综述,纳入295例经AMIM单独检出或CIM检出的异时性寡转移性去势敏感性前列腺癌(omCSPC)男性患者。
  • 采用Mann-Whitney U检验、Pearson χ2检验比较临床与基因组特征,采用Kaplan-Meier法和log-rank检验分析总生存(OS)。

主要发现

  • CIM检出omCSPC者Gleason分级分组显著更高(p=0.032)。
  • CIM检出者确诊omCSPC时PSA为8.0 ng/ml,AMIM检出者为1.7 ng/ml(p<0.001)。
  • CIM检出者致病性TP53突变占28%,AMIM检出者占17%(p=0.030)。
  • CIM检出者10年OS为85%,AMIM检出者为100%(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In metastatic castration-sensitive prostate cancer (mCSPC), disease volume plays an integral role in guiding treatment recommendations, including selection of docetaxel therapy, metastasis-directed therapy, and radiation to the prostate. Although there are multiple definitions of disease volume, they have commonly been studied in the context of metastases detected via conventional imaging (CIM). One such numeric definition of disease volume, termed oligometastasis, is heavily dependent on the sensitivity of the imaging modality. We performed an international multi-institutional retrospective review of men with metachronous oligometastatic CSPC (omCSPC), detected via either advanced molecular imaging alone (AMIM) or CIM. Patients were compared with respect to clinical and genomic features using the Mann-Whitney U test, Pearson's χ2 test, and Kaplan-Meier overall survival (OS) analyses with a log-rank test. A total of 295 patients were included for analysis. Patients with CIM-omCSPC had significantly higher Gleason grade group (p = 0.032), higher prostate-specific antigen at omCSPC diagnosis (8.0 vs 1.7 ng/ml; p < 0.001), more frequent pathogenic TP53 mutations (28% vs 17%; p = 0.030), and worse 10-yr OS (85% vs 100%; p < 0.001). This is the first report of clinical and biological differences between AMIM-detected and CIM-detected omCSPC. Our findings are particularly important for ongoing and planned clinical trials in omCSPC. PATIENT SUMMARY: Metastatic prostate cancer with just a few metastases only detected via newer scanning methods (called molecular imaging) is associated with fewer high-risk DNA mutations and better survival in comparison to metastatic cancer detected via conventional scan methods.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sutera P, Song Y, Van der Eecken K, et al. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol. 2023. PMID: 37173210. doi:10.1016/j.eururo.2023.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。